<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873923</url>
  </required_header>
  <id_info>
    <org_study_id>IB2012-DATECAN-2</org_study_id>
    <nct_id>NCT02873923</nct_id>
  </id_info>
  <brief_title>Variability of Definitions for Survival Endpoints and Surrogate Properties for OS in Sarcoma Trials: a Meta-analysis</brief_title>
  <acronym>DATECAN-2</acronym>
  <official_title>Survival Endpoints in Randomized Clinical Trials in Sarcoma Patients: Meta-analyses for the Assessment of the Impact Various Definitions on Trials' Results and of Surrogate Properties for OS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ligue contre le cancer, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DATECAN-2 project aims at assessing the surrogate properties for OS of several&#xD;
      time-to-event endpoints through meta-analyses of completed and published randomized&#xD;
      controlled trials. Two main cancer localization are concerned: breast cancer and soft-tissue&#xD;
      sarcomas. The impact of survival endpoints' definitions on the trials' results and&#xD;
      conclusions will also be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: In randomized phase III cancer clinical trials, the validated and most&#xD;
      objectively defined evaluation criterion is overall survival (OS). Therapeutic progress,&#xD;
      which in certain contexts has significantly reduced overall mortality, the development of new&#xD;
      types of cytostatic treatments (as opposed to cytotoxic treatments), the current context of&#xD;
      strategic trials and the multiplication of lines of treatment have resulted in the necessity&#xD;
      of creating new evaluation criteria measuring treatment efficacy sooner and more precisely:&#xD;
      for example, progression-free survival in second line treatment, duration of local control,&#xD;
      and time until treatment failure. These types of surrogate endpoints are commonly used in&#xD;
      phase II trials but are increasingly being used to replace overall survival in phase III&#xD;
      trials. Their development is strongly influenced by the necessity of reducing clinical trial&#xD;
      duration, cost and number of patients.&#xD;
&#xD;
      However while these survival endpoints are frequently used, they are often poorly defined and&#xD;
      when they are, the definition can vary between trials. The lack of standardized definitions&#xD;
      constitutes a clear limitation to their use as primary endpoints. Furthermore, this&#xD;
      variability of definitions can have an important impact on trials' results by affecting power&#xD;
      and estimation.&#xD;
&#xD;
      The ongoing DATECAN-1 project is aimed at providing guidelines for the definitions of&#xD;
      survival endpoints in cancer trials (2009-2011 grant from the French League Against Cancer).&#xD;
      Standardized recommendations will be available for survival endpoints commonly used for&#xD;
      various cancer sites including pancreas, sarcomas and GIST (gastro-intestinal stromal&#xD;
      tumors), breast, stomach.&#xD;
&#xD;
      Objectives: Following these guidelines, one can wonder how sensitive are these definitions?&#xD;
      Or similarly, how do survival endpoints' definitions impact the conclusions of clinical&#xD;
      trials? The objective of the DATECAN-2 study is to assess the impact of survival endpoints'&#xD;
      definitions, as defined by the consensus guidelines, on trials' results and conclusions. The&#xD;
      second objective is to study the surrogate properties for OS of these survival endpoints.&#xD;
&#xD;
      Methods: The evaluation of the impact of the variability of the definitions of survival&#xD;
      endpoints on the results of clinical trials will be evaluated using individual data from&#xD;
      datasets collected in the context of published (academic) clinical trials, as well as&#xD;
      simulated datasets.&#xD;
&#xD;
      After approval by the sponsors, data will be analyzed using various endpoints' definitions&#xD;
      including (i) the definition provided in the publication and (ii) the definition provided by&#xD;
      the guidelines. We will identify which survival endpoint, as defined by the guidelines, was&#xD;
      reported in the publication. Next, realistic data sets will be simulated that mimic data that&#xD;
      could be observed in randomized cancer trials. We will generate data sets with varying&#xD;
      proportions of events (number of deaths, progression, etc) depending on the survival&#xD;
      endpoints of interest. Survival endpoints will be compared across treatment arms using the&#xD;
      definition provided by the guidelines, and based on various scenarios (different proportions&#xD;
      of events, length of follow-up, etc).&#xD;
&#xD;
      Using data from published data sets, we will evaluate survival endpoints in terms of&#xD;
      surrogate candidates for OS. A hierarchy of the survival endpoints will be proposed according&#xD;
      to their surrogate properties based on two criteria: the Fleming classification and the R2&#xD;
      value for validated surrogates. Depending on the number of clinical trials, single-trial or&#xD;
      multiple-trials method will be employed. Single-trial methodology relies on Prentice criteria&#xD;
      and Freedman's proportion of treatment effect (PTE) explained by the surrogate. In case of&#xD;
      multiple trials, and when meta-analysis of clinical trials is feasible, surrogacy of&#xD;
      candidate endpoints for OS will also be explored using weighted linear regression, which&#xD;
      jointly estimates the level of association between endpoints and the trial-level association&#xD;
      (R²) between treatment effects on the candidate surrogate and the final endpoint. Based on&#xD;
      these results (R² and PTE), survival endpoints will be ranked according to their surrogate&#xD;
      capabilities for OS.&#xD;
&#xD;
      Expected results: Analysis of the sensitivity of clinical trials' results to the survival&#xD;
      endpoints' definitions and surrogacy properties are key features when designing and&#xD;
      conducting clinical trials. Based on our results, we will be able to anticipate the expected&#xD;
      impact of the definitions on effect size, sample size and power. We will be able to estimate&#xD;
      these parameters more precisely and as such provide more efficient estimations. Similarly our&#xD;
      assessment of the surrogate properties of the survival endpoints should help us for the&#xD;
      selection of the best surrogate marker for OS, and thus limit biases. Overall, by producing&#xD;
      less biased results and more efficient designs, our project should have an important role in&#xD;
      the design and conduct of future randomized trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">January 1, 2017</completion_date>
  <primary_completion_date type="Actual">January 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 18 months following randomization</time_frame>
    <description>Number of deaths</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Up to 12 months following randomization</time_frame>
    <description>Number of progressions or deaths. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2846</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with a metastatic soft tissue sarcoma</arm_group_label>
    <description>All patients included in eligible clinical trials of the meta-analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>undefined</intervention_name>
    <description>Chemotherapy drug (meta-analyses of randomized trials)</description>
    <arm_group_label>Patients with a metastatic soft tissue sarcoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients included in phase III randomized clinical trials assessing patients with&#xD;
        metastatic soft-tissue sarcoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        No patient will be included.&#xD;
&#xD;
        This project concern Phase III clinical trials with following criteria :&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Phase III clinical trials that included overall survival (OS) as endpoint and another&#xD;
             time-to-event endpoint as primary or secondary endpoint&#xD;
&#xD;
          -  Phase III clinical trials that included patients with metastatic soft tissue sarcoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Savina M, Gourgou S, Italiano A, Dinart D, Rondeau V, Penel N, Mathoulin-Pelissier S, Bellera C. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review. Crit Rev Oncol Hematol. 2018 Mar;123:21-41. doi: 10.1016/j.critrevonc.2017.11.014. Epub 2017 Nov 23. Review.</citation>
    <PMID>29482777</PMID>
  </results_reference>
  <results_reference>
    <citation>Savina M, Litière S, Italiano A, Burzykowski T, Bonnetain F, Gourgou S, Rondeau V, Blay JY, Cousin S, Duffaud F, Gelderblom H, Gronchi A, Judson I, Le Cesne A, Lorigan P, Maurel J, van der Graaf W, Verweij J, Mathoulin-Pélissier S, Bellera C. Surrogate endpoints in advanced sarcoma trials: a meta-analysis. Oncotarget. 2018 Oct 2;9(77):34617-34627. doi: 10.18632/oncotarget.26166. eCollection 2018 Oct 2.</citation>
    <PMID>30349653</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2016</study_first_posted>
  <results_first_submitted>November 25, 2020</results_first_submitted>
  <results_first_submitted_qc>November 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 21, 2020</results_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clinical trial</keyword>
  <keyword>surrogate endpoints</keyword>
  <keyword>meta analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients With a Metastatic Soft Tissue Sarcoma</title>
          <description>All patients included in eligible clinical trials of the meta-analysis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2846"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2846"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients With a Metastatic Soft Tissue Sarcoma</title>
          <description>All patients included in eligible clinical trials of the meta-analysis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2846"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2846"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1423"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Number of deaths</description>
        <time_frame>up to 18 months following randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With a Metastatic Soft Tissue Sarcoma</title>
            <description>All patients included in eligible clinical trials of the meta-analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Number of deaths</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2846"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Number of progressions or deaths. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>Up to 12 months following randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With a Metastatic Soft Tissue Sarcoma</title>
            <description>All patients included in eligible clinical trials of the meta-analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Number of progressions or deaths. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2846"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Individual-level Association</title>
        <description>Individual-level association between 12-month progression-free survival and 18-month overall survival</description>
        <time_frame>within 18 months following randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With a Metastatic Soft Tissue Sarcoma</title>
            <description>All patients included in eligible clinical trials of the meta-analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Individual-level Association</title>
          <description>Individual-level association between 12-month progression-free survival and 18-month overall survival</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2846"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.63" upper_limit="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Correlation coefficient</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
            <other_analysis_desc>As of today, the meta-analytic surrogacy evaluation scheme proposed by Buyse and Burzykowski et al. is considered as the most statistically rigorous method for the validation of surrogate endpoints. This approach requires individual-patient data (IPD) from multiple randomized clinical trials (RCT) with similar design and treatment to address surrogacy from a multi-level framework. At the patient level, the surrogate endpoint should be correlated and predictive of the final endpoint regardless of the treatment (individual level association). At the trial level, the treatment effect on the surrogate endpoint should be correlated and predictive of the treatment effect on the final endpoint (trial-level association). Individual-level and trial-level associations estimated using weighted linear regression and the two-stage model introduced by Buyse and Burzykowski.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Trial-level Association</title>
        <description>Trial-level association between 12-month progression-free survival and 18-month overall survival</description>
        <time_frame>within 18 months following randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With a Metastatic Soft Tissue Sarcoma</title>
            <description>All patients included in eligible clinical trials of the meta-analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Trial-level Association</title>
          <description>Trial-level association between 12-month progression-free survival and 18-month overall survival</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2846"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>correlation coefficient</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>0.005</ci_upper_limit>
            <other_analysis_desc>As of today, the meta-analytic surrogacy evaluation scheme proposed by Buyse and Burzykowski et al. is considered as the most statistically rigorous method for the validation of surrogate endpoints. This approach requires individual-patient data (IPD) from multiple randomized clinical trials (RCT) with similar design and treatment to address surrogacy from a multi-level framework. At the patient level, the surrogate endpoint should be correlated and predictive of the final endpoint regardless of the treatment (individual level association). At the trial level, the treatment effect on the surrogate endpoint should be correlated and predictive of the treatment effect on the final endpoint (trial-level association). Individual-level and trial-level associations estimated using weighted linear regression and the two-stage model introduced by Buyse and Burzykowski.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 18 months following randomization</time_frame>
      <desc>This study is a meta-analysis focussing on the association between progression-free survival and overall survival. As such, we did not report on the safety.&#xD;
Serious and Other (Not Including Serious) Adverse Events were not monitored/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Patients With a Metastatic Soft Tissue Sarcoma</title>
          <description>All patients included in eligible clinical trials of the meta-analysis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1704" subjects_at_risk="2846"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Carine Bellera</name_or_title>
      <organization>Institut Bergonié</organization>
      <phone>33 5 56 33 04 95</phone>
      <email>c.bellera@brodeaux.unicancer.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

